Background
Present address: Scientific director of Istituto Nazionale Tumori- IRCCS- Fondazione G. Pascale, Naples, Italy.These authors contributed equally.Maintaining angiogenesis inhibition and switching the chemotherapy backbone represent the current second-line therapy in patients with 